ImmunoPrecise Antibodies Ltd. Clarifies Share Count
Ticker: HYFT · Form: 6-K · Filed: Feb 3, 2025 · CIK: 1715925
Sentiment: neutral
Topics: amendment, share-count, disclosure
TL;DR
IPA clarifies its outstanding share count to 45.7M shares.
AI Summary
ImmunoPrecise Antibodies Ltd. filed an amendment to its January 2025 Form 6-K on February 3, 2025. The amendment's sole purpose is to add a sentence to a previously filed press release, clarifying that the company currently has 45,765,118 common shares issued and outstanding.
Why It Matters
This filing provides crucial transparency for investors regarding the exact number of outstanding shares, which impacts ownership percentages and potential dilution.
Risk Assessment
Risk Level: low — The filing is a minor amendment to clarify existing information and does not introduce new risks.
Key Numbers
- 45,765,118 — Common Shares Outstanding (This is the updated and clarified number of shares issued and outstanding as of the filing date.)
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the Form 6-K
- 45,765,118 (dollar_amount) — Number of common shares issued and outstanding
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is an amendment to a previous filing, solely to add a sentence specifying the company's current number of issued and outstanding common shares.
When was the original Form 6-K filed?
The original Form 6-K was furnished to the SEC on January 27, 2025.
What specific information is being added by this amendment?
The amendment adds a sentence to a press release clarifying that ImmunoPrecise Antibodies Ltd. currently has 45,765,118 common shares issued and outstanding.
What is the company's principal executive office address?
The company's principal executive office is located at Industrious 823 Congress Ave Suite 300 Austin, Texas 78701.
Does the company file annual reports under Form 20-F or Form 40-F?
The registrant indicates it files annual reports under Form 20-F.
Filing Stats: 283 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2025-02-03 12:29:26
Filing Documents
- press_release_feb_3_2025.htm (6-K) — 26KB
- ipa-ex99_1.htm (EX-99.1) — 17KB
- 0000950170-25-012156.txt ( ) — 44KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: February 3, 2025 By: /s/ Jennifer Bath Name: Jennifer Bath Title: President and Chief Executive Officer